Lv01
0 积分 2025-11-08 加入
CLSI POCT05 Performance Metrics for Continuous Interstitial Glucose Monitoring
1小时前
求助中
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
21天前
已完结
A safety estimand for late phase clinical trials where the analysis period varies over the subjects
1个月前
已完结
A safety estimand for late phase clinical trials where the analysis period varies over the subjects
1个月前
已完结
Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trials
1个月前
已完结
Acne vulgaris
2个月前
已完结
Atrasentan in Patients with IgA Nephropathy
2个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
2个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
2个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2个月前
已完结
皖公网安备34019202002308
